New Phase 3 trial: A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery — Harrow Inc
Why now
Thesis: Phase 3 trial registration for Harrow's TRIESENCE
Catalyst to watch: Enrollment completion or data readout
Main risk: Enrollment status only, no data
Why it matters
Phase 3 trial registration for Harrow's TRIESENCE; enrollment status only, no data.
Details
Sponsor: Harrow Inc; Status: Enrolling By Invitation; Conditions: Postoperative Ocular Inflammation, Postoperative Ocular Pain; Interventions: Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension); Enrollment: 250 (estimated); First posted: 2026-09-22; NCT: NCT07832552
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-22 12:00 UTC